Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Pigment Epithelium Tears Secondary to AMD
NCT01914159Phase 2Completed
- Sponsor
- University Hospital Bonn
- Start
- Feb 2013
- Primary completion
- Mar 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in age-related macular degeneration (AMD), sponsored by University Hospital Bonn. Started Feb 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01914159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01914159.